AMRX Stock News & Catalysts – Amneal Pharmaceuticals

FEATURED

Amneal Reports Third Quarter 2026 Financial Results

– Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) –– Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 –– Updating 2026 Full Year Guidance –

Summary

Nov 3, 2026, 6:00 AM ·Globe Newswire

RECENT

Amneal to Report Third Quarter 2026 Results on November 3, 2026

BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced it will report third quarter 2026 financial results on

Oct 8, 2026, 8:00 AM ·Globe Newswire

Amneal Announces FDA Approval and Launch of Lanreotide Injection

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal

Sep 18, 2026, 4:01 PM ·Globe Newswire

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal") on behalf of the company’s current shareholders.The investigation seeks to determine whether Amneal or the company’s officers

Aug 19, 2026, 8:00 AM ·Business Wire

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal’s growth profile into the 2030s BRIDGEWATER, N.J.,

Aug 10, 2026, 8:00 AM ·Globe Newswire

Amneal Reports Second Quarter 2026 Financial Results

– Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 –– Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 –– Raising 2026 Full Year Guidance –– Successful

Jul 30, 2026, 6:00 AM ·Globe Newswire

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal") on behalf of the company’s current shareholders. The investigation seeks to determine whether Amneal or the company’s

Jul 23, 2026, 1:27 PM ·Business Wire

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolioPortfolio now positioned to address the

Jul 17, 2026, 8:00 AM ·Globe Newswire

Amneal to Report Second Quarter 2026 Results on July 30, 2026

BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced it will report second quarter 2026 financial results on

Jul 9, 2026, 4:05 PM ·Globe Newswire

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more "Good ON" time with fewer daily doses compared with immediate-release levodopa/carbidopaHopledo® is

Jun 29, 2026, 3:00 AM ·Globe Newswire

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients NationwideNASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- Dispensary of Hope announced the launch of

Jun 10, 2026, 10:09 AM ·PRNewswire

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsSubstantial increases in daily "Good On"

Jun 5, 2026, 8:00 AM ·Globe Newswire

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitutionCompetitive Generic Therapy approval provides 180 days of market exclusivity and further expands

Jun 4, 2026, 8:00 AM ·Globe Newswire

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced that Chirag Patel, Co-Chief Executive and President, will participate and

Jun 1, 2026, 8:00 AM ·Globe Newswire

Amneal Reports First Quarter 2026 Financial Results

‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒‒ No Change from Preliminary Results Previously

May 7, 2026, 4:01 PM ·Globe Newswire

Amneal Pharmaceuticals, Inc. AMRX · News